Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 412.5 GBX -1.43% Market Closed
Market Cap: 434.6m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

EV/FCFF
Enterprise Value to FCFF

-6.4
Current
-7.4
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-6.4
=
Enterprise Value
458.5m GBX
/
FCFF
-72.1m GBP
All Countries
Close
Market Cap EV/FCFF
UK
Oxford BioMedica PLC
LSE:OXB
434.4m GBP -6.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -236 180.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 22.5
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD -84.4
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 10.9
US
Epizyme Inc
F:EPE
94.1B EUR -474.9
AU
CSL Ltd
ASX:CSL
137.3B AUD 65.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 24.5
US
Seagen Inc
F:SGT
39.3B EUR -57.3
NL
argenx SE
XBRU:ARGX
34.1B EUR -100.8
 
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/FCFF: 31.2
Negative Multiple: -6.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -236 180.8
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -84.4
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.9
AU
CSL Ltd
ASX:CSL
65.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3
NL
argenx SE
XBRU:ARGX
Negative Multiple: -100.8

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More